Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYS-ON: SC Natalizumab in RRMS
NCT05532163Phase 4Terminated
- Sponsor
- Biogen
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Cumulative Number of Active Lesions (CUALs) Through Week 24. Started Jan 2023; status: terminated.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05532163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532163.